Process development in the QbD paradigm: Role of process integration in process optimization for production of biotherapeutics

Abstract

Biotherapeutics have become the focus of the pharmaceutical industry due to their proven effectiveness in managing complex diseases. Downstream processes of these molecules consist of several orthogonal, high resolution unit operations designed so as to be able to separate variants having very similar physicochemical properties. Typical process development involves optimization of the individual unit operations based on Quality by Design principles in order to define the design space within which the process can deliver product that meets the predefined specifications. However, limited efforts are dedicated to understanding the interactions between the unit operations. This paper aims to showcase the importance of understanding these interactions and thereby arrive at operating conditions that are optimal for the overall process. It is demonstrated that these are not necessarily same as those obtained from optimization of the individual unit operations. Purification of Granulocyte Colony Stimulating Factor (G-CSF), a biotherapeutic expressed in E. coli., has been used as a case study. It is evident that the suggested approach results in not only higher yield (91.5 vs. 86.4) but also improved product quality (% RP-HPLC purity of 98.3 vs. 97.5) and process robustness. We think that this paper is very relevant to the present times when the biotech industry is in the midst of implementing Quality by Design towards process development. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 32:355-362, 2016.

Integrated continuous processing of proteins expressed as inclusion bodies: GCSF as a case study

“…The selected two‐step chromatography process was considered as a single system and an integrated optimization of the same was performed. A recent report has highlighted the enhanced optimality in performance that can be achieved when performing integrated optimization vs. the traditional approach of optimizing a single step at a time . Optimization was performed using a three parameter (CEX Elution pH, CEX Elution salt concentration, and HEA elution pH), three level integrated DOE with Central Composite Design .…”

“…For HEA elution, only the elution pH was considered and the elution salt concentration was fixed at 100 mM based on previous findings . Ranges for CEX elution pH (5–5.7), CEX elution salt concentration (250–400 mM), and HEA elution pH (4–4.7) were based on previously published reports . Recovery (%) and Purity (%) were taken as the output parameters for the DOE study.…”

Regulatory Pathway for Licensing Biotherapeutics in Mexico

“…Process for Drug Substance (DS) and Drug Product (DP): This section includes process mapping steps including the critical process parameters (CPPs) for each critical process step. The acceptance criteria of the process validation protocol should be based on the quality target product profiles (QTPPs) intervals of the Critical Quality Attributes (CQAs) to demonstrate the consistency of manufacturing with at least three batches documented in the corresponding validation report ( 24 , 29 – 31 ).…”

Model-Based Design of Process Strategies for Cell Culture Bioprocesses: State of the Art and New Perspectives

“…Even though the prediction of the resin's porosity was of insufficient accuracy, the simulation allowed deeper understanding of the process, which leads to a more efficient determination of the Design Space. In the general procedure of process development, the use of complex, demanding, and time-consuming methods based on DoE tools has become common practice, although mathematical models are already used in the operation, control, and optimization of existing production processes [47,58,59]. Novel tools for process development and optimization combine DoE tools with a growth model.…”